TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32406989

Group type: EXPERIMENTAL
Intervention: Health facility delivery of CHoBI7 plus mHealth (weekly voice and text messages) (no home visits)
Number of subjects: 1468

Group type: EXPERIMENTAL
Intervention: Health facility delivery of CHoBI7 plus two home visits and mHealth
Number of subjects: 1468

Group type: COMPARATOR
Intervention: Standard recommendation on oral rehydration solution use
Number of subjects: 1468
Study: 34488548

Group type: EXPERIMENTAL
Intervention: Brief intervention (20 to 30 minutes)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (5 minutes of brief advice)
Number of subjects: 44
Study: 34915725

Group type: EXPERIMENTAL
Intervention: Group Interpersonal Psychotherapy (IPT-G)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy adherence
Number of subjects: 24
Study: 34472894

Group type: EXPERIMENTAL
Intervention: Good Behavior Game (GBG) intervention
Number of subjects: 3084

Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 3084
Study: 32912218

Group type: EXPERIMENTAL
Intervention: 12-week complex interventions including structured assessment, health education, goal empowerment, and care coordination supported by a health-social team
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual discharge care and monthly social call
Number of subjects: 75
Study: 35831850

Group type: EXPERIMENTAL
Intervention: Vitamin B6 (80 mg daily)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 33152774

Group type: EXPERIMENTAL
Intervention: M-ESD
Number of subjects: 60

Group type: COMPARATOR
Intervention: C-ESD
Number of subjects: 60
Study: 35997099

Group type: EXPERIMENTAL
Intervention: Advanced counseling (whistling Flo-tone + smartphone application combined with traditional verbal counseling)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional verbal counseling
Number of subjects: 100
Study: 33463912

Group type: EXPERIMENTAL
Intervention: Interval exercise (57.6 kJ/exercise session)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Continuous exercise (12 min)
Number of subjects: 11
Study: 32159820

Group type: EXPERIMENTAL
Intervention: Wavefront-Guided PRK (WFG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Wavefront-Optimized PRK (WFO)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both WFG and WFO PRK
Number of subjects: 20
Study: 34473302

Group type: EXPERIMENTAL
Intervention: Higher urine interleukin‐18
Number of subjects: 2377

Group type: EXPERIMENTAL
Intervention: Higher kidney injury molecule‐1 (KIM-1)
Number of subjects: 2377

Group type: EXPERIMENTAL
Intervention: Higher neutrophil gelatinase‐associated lipocalin (NGAL)
Number of subjects: 2377

Group type: EXPERIMENTAL
Intervention: Higher monocyte chemoattractant protein‐1 (MCP‐1)
Number of subjects: 2377

Group type: EXPERIMENTAL
Intervention: Lower urine uromodulin (UMOD)
Number of subjects: 2377

Group type: EXPERIMENTAL
Intervention: Higher serum fibroblast growth factor‐23
Number of subjects: 2377
Study: 33826436

Group type: EXPERIMENTAL
Intervention: IOPTx™ system (wearable electroceutical treatment)
Number of subjects: 0
Study: 32572040

Group type: EXPERIMENTAL
Intervention: Genes controlling ginsenoside biosynthesis in ginseng
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Genes controlling fiber length in cotton
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Genes controlling grain yield in maize
Number of subjects: 3
Study: 35633978

Group type: EXPERIMENTAL
Intervention: Dance and yoga intervention (twice a week for 8 months)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 121
Study: 33077708

Group type: EXPERIMENTAL
Intervention: Multiple myeloma patients
Number of subjects: 167

Group type: COMPARATOR
Intervention: Noncancer patients
Number of subjects: 167
Study: 34966032

Group type: EXPERIMENTAL
Intervention: LEADS curriculum
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: TeamSTEPPS curriculum
Number of subjects: 110

Group type: COMPARATOR
Intervention: Active controls (no leadership curriculum)
Number of subjects: 110
Study: 33966242

Group type: EXPERIMENTAL
Intervention: INVOS neonatal sensor with cover
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: INVOS neonatal sensor without cover
Number of subjects: 0

Group type: COMPARATOR
Intervention: OxiplexTS reference oximeter
Number of subjects: 0
Study: 36429876

Group type: EXPERIMENTAL
Intervention: Web-based interactive weight loss coaching
Number of subjects: 1499

Group type: COMPARATOR
Intervention: Non-interactive web-based health program
Number of subjects: 1499
Study: 34739635

Group type: EXPERIMENTAL
Intervention: Molecular-based recommended therapy (MBRT) proposed after molecular profiling
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Discontinuation of MBRT
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Actionable molecular alterations identified
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: High-throughput sequencing
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Criteria for clinical trial enrollment
Number of subjects: 141
Study: 32559515

Group type: EXPERIMENTAL
Intervention: Prolonged-release fampridine (PR-fampridine)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Prolonged-release fampridine (PR-fampridine) in a sub-group (n = 8)
Number of subjects: 61
Study: 36138465

Group type: EXPERIMENTAL
Intervention: UFNET rate set on the CRRT of at least 100 ml h‐1 between inclusion and H72 of inclusion if hemodynamically tolerated based on a protocolized hemodynamic protocol.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Protocolized fluid removal with an UFNET rate set to 0‐25 ml h‐1 between inclusion and H72 of inclusion.
Number of subjects: 0
Study: 34556382

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine admixed with bupivacaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ropivacaine
Number of subjects: 100
Study: 33673567

Group type: EXPERIMENTAL
Intervention: Received caffeine (3 mg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Informed caffeine (placebo but participants were told it was caffeine)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (cellulose, 3 mg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Informed caffeine (placebo)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo, Received caffeine, Informed caffeine
Number of subjects: 12
Study: 34313619

Group type: EXPERIMENTAL
Intervention: Ferrous supplementation
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Methylphenidate (short-acting, twice daily)
Number of subjects: 52
Study: 33896630

Group type: EXPERIMENTAL
Intervention: B. coagulans-70
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (other tested strains)
Number of subjects: 30
Study: 32900564

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg 2 hours after TKA, followed by 200 mg 6 hours later
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group received 400 mg of celecoxib the second day after surgery
Number of subjects: 0
Study: 32171411

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting
Number of subjects: 0
Study: 34286867

Group type: EXPERIMENTAL
Intervention: Laser-assisted scaling and root planing (L-SRP)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional scaling and root planing (C-SRP)
Number of subjects: 26
Study: 33705465

Group type: EXPERIMENTAL
Intervention: Integrated collaborative care intervention
Number of subjects: 409
Study: 34992671

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine combined with propofol, remifentanil, and atracurium (Experimental Group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Propofol, remifentanil, and atracurium only (Control Group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ultrasound and spiral CT images before reconstruction
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ultrasound and spiral CT images after reconstruction
Number of subjects: 80
Study: 34895998

Group type: EXPERIMENTAL
Intervention: Diet patterned after the 2010 Dietary Guidelines for Americans (DGA)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Typical American Diet (TAD)
Number of subjects: 44
Study: 34161737

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (40 minutes, 50-70% heart rate reserve, 3-4 times per week)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 35649615

Group type: EXPERIMENTAL
Intervention: Personal health coaching by telephone and access to a smartphone and web application for 1 year
Number of subjects: 90

Group type: COMPARATOR
Intervention: Access to the application for 1 year and a one-time written diet and exercise recommendation
Number of subjects: 90
Study: 33297757

Group type: EXPERIMENTAL
Intervention: Hypnofertility-based nursing care
Number of subjects: 61
Study: 32386082

Group type: EXPERIMENTAL
Intervention: Post-operative intermediate care
Number of subjects: 286

Group type: COMPARATOR
Intervention: Standard surgical ward care
Number of subjects: 286
Study: 36478180

Group type: EXPERIMENTAL
Intervention: Tirzepatide (once-weekly subcutaneous)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33949065

Group type: EXPERIMENTAL
Intervention: Group-based multi-component psycho-educational intervention (GMC-PEI)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (leaflets containing information about dementia)
Number of subjects: 54
Study: 32539096

Group type: EXPERIMENTAL
Intervention: Viltolarsen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34801917

Group type: EXPERIMENTAL
Intervention: Midodrine (10 mg every 8 hours)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 62
Study: 34170908

Group type: EXPERIMENTAL
Intervention: IV furosemide infusion
Number of subjects: 94

Group type: COMPARATOR
Intervention: IV placebo infusion
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 94
Study: 32216801

Group type: EXPERIMENTAL
Intervention: Quadtree algorithm for population sampling frame
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uniform grid cells (UGC) approach (1×1 km and 3×3 km)
Number of subjects: 0
Study: 35113238

Group type: EXPERIMENTAL
Intervention: Total Hip Arthroplasty (THA)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Hemiarthroplasty (HA)
Number of subjects: 132
Study: 32907500

Group type: EXPERIMENTAL
Intervention: 200 mg donafenib twice daily for 24 weeks
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 300 mg donafenib twice daily for 24 weeks
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 300 mg donafenib
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 200 mg donafenib
Number of subjects: 35
Study: 35275569

Group type: EXPERIMENTAL
Intervention: 500 pulses
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 1,000 pulses
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 1,500 pulses
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 2,000 pulses
Number of subjects: 13
Study: 32074977

Group type: EXPERIMENTAL
Intervention: Calanus oil supplementation plus exercise training
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo (sunflower oil) plus exercise training
Number of subjects: 55
Study: 32151176

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Vincristine
Number of subjects: 120
Study: 35569283

Group type: EXPERIMENTAL
Intervention: Sequential treatment (n = 151)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Combination treatment (n = 149)
Number of subjects: 300
Study: 35507037

Group type: EXPERIMENTAL
Intervention: Ipsilateral hamstring graft
Number of subjects: 100

Group type: COMPARATOR
Intervention: Contralateral hamstring graft
Number of subjects: 100
Study: 32161992

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 11
Study: 34480785

Group type: EXPERIMENTAL
Intervention: Intensive nutritional education (at every outpatient visit)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Usual nutritional education (once a year)
Number of subjects: 96
Study: 32167038

Group type: EXPERIMENTAL
Intervention: One dose of oral cholera vaccine (OCV)
Number of subjects: 211
Study: 35862082

Group type: EXPERIMENTAL
Intervention: Empagliflozin-ramipril combination treatment
Number of subjects: 30
Study: 33914057

Group type: EXPERIMENTAL
Intervention: 59.4 Gy radiotherapy + concurrent and/or adjuvant temozolomide
Number of subjects: 751

Group type: COMPARATOR
Intervention: 59.4 Gy radiotherapy
Number of subjects: 751
Study: 34756518

Group type: EXPERIMENTAL
Intervention: Combined group (local anesthesia with 0.5% lidocaine + oral 200 mg Celecoxib + intravenous 40 mg parecoxib sodium + continuous intravenous 0.5 μg/kg/h dexmedetomidine)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Preemptive group (local anesthesia with 0.5% lidocaine + oral 200 mg Celecoxib + intravenous 40 mg parecoxib sodium)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Conventional group (local anesthesia with 0.5% lidocaine)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Combined group
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Preemptive group
Number of subjects: 128

Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 128
Study: 33187485

Group type: EXPERIMENTAL
Intervention: Digital education program delivering FP/RH information and economic empowerment training through storytelling.
Number of subjects: 6000
Study: 36166756

Group type: EXPERIMENTAL
Intervention: Self-distanced reflections
Number of subjects: 257

Group type: COMPARATOR
Intervention: Self-immersed reflections
Number of subjects: 257
Study: 34454710

Group type: EXPERIMENTAL
Intervention: Voice alerts
Number of subjects: 28

Group type: COMPARATOR
Intervention: Auditory icons
Number of subjects: 28
Study: 32541348

Group type: EXPERIMENTAL
Intervention: Lateral pelvic elevation on the ipsilateral measurement side
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Anterior activity during lateral pelvic elevation
Number of subjects: 12
Study: 33340750

Group type: EXPERIMENTAL
Intervention: Three virtual visits with a health educator in the 3rd trimester of pregnancy, at 3–4 weeks, and 3–4 months postpartum, along with continuous multimedia education through text messaging, print material, and videos.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced safety education control group.
Number of subjects: 0
Study: 35909251

Group type: EXPERIMENTAL
Intervention: Sponge-assisted surgery
Number of subjects: 150

Group type: COMPARATOR
Intervention: Trendelenburg surgery
Number of subjects: 150
Study: 33977284

Group type: EXPERIMENTAL
Intervention: RTB101 10 mg once daily
Number of subjects: 1676

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1676

Group type: EXPERIMENTAL
Intervention: RTB101 10 mg in combination with everolimus 0.1 mg once daily
Number of subjects: 1676
Study: 32468579

Group type: EXPERIMENTAL
Intervention: Talazoparib
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Talazoparib exposure (Cavg,t)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Absence of visceral disease
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Lower baseline lactate dehydrogenase levels
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Disease-free interval >12 months
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Recommended starting dose of talazoparib
Number of subjects: 285
Study: 34662695

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Tomatis sound therapy (TST)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Combination of HBOT and TST
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 146
Study: 33910653

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mandibular advancement devices
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nasal surgery
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Soft palate, tongue base or mandibular surgery
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hypoglossal nerve stimulation
Number of subjects: 60
Study: 35305913

Group type: EXPERIMENTAL
Intervention: IV ibuprofen 800 mg infusion
Number of subjects: 50

Group type: COMPARATOR
Intervention: IV paracetamol 1 g infusion
Number of subjects: 50
Study: 34428241

Group type: EXPERIMENTAL
Intervention: Family-centered care model (FCCM)
Number of subjects: 379

Group type: COMPARATOR
Intervention: Standard-of-care (SOC)
Number of subjects: 379
Study: 37714931

Group type: EXPERIMENTAL
Intervention: Street football training (ST)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Grass football training (GR)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Inactive control group (CO)
Number of subjects: 39
Study: 34185831

Group type: EXPERIMENTAL
Intervention: Cannabis cigarette with 5.9% Δ9‐tetrahydrocannabinol (THC)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Cannabis cigarette with 13.4% Δ9‐tetrahydrocannabinol (THC)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo (0.02% THC)
Number of subjects: 191
Study: 33736547

Group type: EXPERIMENTAL
Intervention: Cross‐sectorial lung team (CLT)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 113
Study: 32195949

Group type: EXPERIMENTAL
Intervention: Acupressure wrist‐ankle strap
Number of subjects: 78

Group type: COMPARATOR
Intervention: Nonacupressure wrist‐ankle strap
Number of subjects: 78
Study: 35613998

Group type: EXPERIMENTAL
Intervention: SBRT (8 Gy x 3 fractions) plus systemic therapy
Number of subjects: 384

Group type: COMPARATOR
Intervention: Systemic therapy alone
Number of subjects: 384
Study: 32674691

Group type: EXPERIMENTAL
Intervention: Breakfast (B) - Individualised breakfast (583±54 kcal; 8-9am) and lunch (874±80 kcal; 12-2pm)
Number of subjects: 11

Group type: COMPARATOR
Intervention: No Breakfast (NB) - Fasting until 12pm and then consuming a standardised lunch (1457±134 kcal: 12-2pm)
Number of subjects: 11
Study: 32064639

Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 8732

Group type: EXPERIMENTAL
Intervention: Whole-school intervention only
Number of subjects: 8732

Group type: EXPERIMENTAL
Intervention: Individual intervention only
Number of subjects: 8732

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 8732
Study: 35764191

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (nCRT)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Definitive chemoradiotherapy (dCRT)
Number of subjects: 256
Study: 34180122

Group type: EXPERIMENTAL
Intervention: Overlap transition (IDeg 1:1 at pump basal dose, pump continued for first 48 hours with gradual basal reduction)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard of care (discontinued insulin pump and started IDeg in 1:1 dose)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 32706198

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation intervention using the BrainHQTM web-based platform (n = 23)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (n = 24)
Number of subjects: 47
Study: 35696837

Group type: EXPERIMENTAL
Intervention: Imagery-enhanced cognitive behavioral group therapy (IE-CBGT)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Verbal-based cognitive behavioral group therapy (VB-CBGT)
Number of subjects: 107
Study: 33619188

Group type: EXPERIMENTAL
Intervention: Enhanced usual care with in-person education about conservative kidney management and advance care planning (COPE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 32134321

Group type: EXPERIMENTAL
Intervention: Supportive-expressive psychotherapy
Number of subjects: 0
Study: 35837705

Group type: COMPARATOR
Intervention: sorafenib
Number of subjects: 0

Group type: COMPARATOR
Intervention: pazopanib
Number of subjects: 0

Group type: COMPARATOR
Intervention: methotrexate and vinblastine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: methotrexate + vinca alkaloids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: cryotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: radiotherapy
Number of subjects: 0
Study: 32806958

Group type: EXPERIMENTAL
Intervention: Disgusted face emoji
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smiling face emoji
Number of subjects: 0

Group type: COMPARATOR
Intervention: Text (no emoji)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High involvement with inspection reports
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low involvement with inspection reports
Number of subjects: 0
Study: 34429515

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactiplantibacillus plantarum HEAL9 and Lacticaseibacillus rhamnosus 271, 109 CFU)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 32081913

Group type: EXPERIMENTAL
Intervention: Living within 3 km of an incinerator
Number of subjects: 19519

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 19519

Group type: EXPERIMENTAL
Intervention: Living in the city
Number of subjects: 19519
Study: 35912473

Group type: EXPERIMENTAL
Intervention: Black VC using Standard American English (SAE)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Black VC using African American English (AAE)
Number of subjects: 282